Compounds > z 300
Page last updated: 2024-12-07

z 300

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Z 300: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124488
SCHEMBL ID4605869
MeSH IDM0208923

Synonyms (18)

Synonym
acetamide, 2-((2-hydroxyethyl)thio)-n-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)-
z-300
brn 4356995
2-((2-hydroxyethyl)thio)-n-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)acetamide
n-(3-(3-(piperidinomethyl)phenoxy)-propyl)-2-(2-hydroxyethyl-1-thio)acetamido.2-(4-hydroxybenzoyl)benzoate
n-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)-2-(2-hydroxyethylthio)acetamide
z 300
L001444
2-(2-hydroxyethylsulfanyl)-n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide
127966-78-3
SCHEMBL4605869
DTXSID10155757
z300
AKOS040754555
2-(2-hydroxyethylsulfanyl)-n-(3-(3-piperidin-1-ylmethyl)phenoxy)propyl)ethanamide
acetamide, 2-[(2-hydroxyethyl)thio]-n-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-
S897X4A4GB
2-[(2-hydroxyethyl)thio]-n-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]acetamide

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of Z-300 was 52% after the oral administration of Z-300, 3 mg/kg."( Pharmacokinetics of a new histamine H2-receptor antagonist, Z-300, in rat and dog.
Furuta, S; Hirabayashi, N; Imamura, F; Ito, T; Kawamata, H; Matsuki, Y; Sano, H; Sugimoto, T; Suzuki, M, 1999)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (83.33)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 92.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index92.59 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index159.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (92.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
roxatidine acetate
roxatidine acetate: structure given in first source		1.9810piperidines
octylamine
octylamine: RN given refers to 1-octylamine. octan-1-amine : An 8-carbon primary aliphatic amine.		210primary aliphatic aminemetabolite
glucosamine
D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.		1.9810D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
ranitidine
Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.		1.9810C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
piperidines
Piperidines: A family of hexahydropyridines.		3.2460
ConditionIndicatedRelationship StrengthStudiesTrials
Gastroduodenal Ulcer
[description not available]		01.9810
Gastric Ulcer
[description not available]		01.9810
Peptic Ulcer
Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		01.9810
Stomach Ulcer
Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		01.9810